Markets

The Virgin Australia float always appeared geared for short-term success — but over the long term, it's a very different story.

While all eyes are on Virgin, another new listing on the ASX this week will push the amount raised by private credit funds beyond $1 billion. And there's more to come.

Fresh from receiving FDA approval, the $1.3 billion medical device company is one of the stronger performers on the ASX this year. But short sellers sniff weakness.

The US President has followed through with earlier threats to attack Iran in a move that could lead to further volatility for markets and the global economy.